Neuroblastoma 3

Common Name(s)

Neuroblastoma 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroblastoma 3" returned 76 free, full-text research articles on human participants. First 3 results:

Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
 

Author(s): Yvette M Carter, Selvi Kunnimalaiyaan, Herbert Chen, T Clark Gamblin, Muthusamy Kunnimalaiyaan

Journal: Cancer Biol. Ther.. 2014 May;15(5):510-5.

 

Neuroblastoma is a common neuroendocrine (NE) tumor that presents in early childhood, with a high incidence of malignancy and recurrence. The glycogen synthase kinase-3 (GSK-3) pathway is a potential therapeutic target, as this pathway has been shown to be crucial in the management ...

Last Updated: 5 May 2014

Go To URL
Palmitic acid and ergosta-7,22-dien-3-ol contribute to the apoptotic effect and cell cycle arrest of an extract from Marthasterias glacialis L. in neuroblastoma cells.
 

Author(s): David M Pereira, Georgina Correia-da-Silva, Patrícia Valentão, Natércia Teixeira, Paula B Andrade

Journal:

 

We describe the effect of a chemically characterized lipophilic extract obtained from Marthasterias glacialis L. against human breast cancer (MCF-7) and human neuroblastoma (SH-SY5Y) cell lines. Evaluation of DNA synthesis revealed that both cell lines were markedly affected in a ...

Last Updated: 25 Dec 2013

Go To URL
Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
 

Author(s): Fei Tan, Reema Wahdan-Alaswad, Shuang Yan, Carol J Thiele, Zhijie Li

Journal: Cancer Sci.. 2013 Dec;104(12):1586-92.

 

Dihydropyrimidinase-like proteins (DPYSLs) are a family of proteins developmentally regulated during maturation of the nervous system. Recently, members of the DPYSL family have been reported to be involved in cancer with low expression of DPYSL1 correlating with poor clinical outcomes ...

Last Updated: 18 Dec 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroblastoma 3" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 28 Apr 2015

Go to URL
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma; Bone Marrow, Sympathetic Nervous System

 

Last Updated: 21 Apr 2015

Go to URL
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma

 

Last Updated: 18 May 2015

Go to URL